The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma

Launched by RUIJIN HOSPITAL · Mar 3, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how a special type of imaging called PET (Positron Emission Tomography) can help predict how well treatments will work for patients with T-NK cell lymphoma, a type of cancer affecting the immune system. The focus is on a specific marker called granzyme B, which is important in understanding the disease. The trial is currently not yet recruiting participants but aims to include adults over 18 years old who have been newly diagnosed with T-NK cell lymphoma or those whose disease has come back after treatment and are about to start immunotherapy.

To be eligible for this trial, participants need to have a confirmed diagnosis of T-NK cell lymphoma and must not have received previous cancer treatments. They also should have complete medical records and give their consent to participate. Those with other serious health issues or recent cancers will not be included. If you join this study, you can expect to undergo PET imaging, which will help researchers gather important information about your condition and treatment response. Your participation could contribute to better understanding and improving future treatments for T-NK cell lymphoma.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age \> 18 years, regardless of gender.
• • 2. Histopathologically confirmed diagnosis of T-NK cell lymphoma.
• • 3. Newly diagnosed and untreated patients or refractory/relapsed patients preparing to undergo immunotherapy.
• • 4. Availability of complete clinicopathological and follow-up data.
• • 5. Signed and dated informed consent form.
• Exclusion Criteria:
• • 1. Patients who have previously received anti-tumor therapy.
• • 2. Patients with a history of other malignancies.
• • 3. Incomplete clinical information or imaging data.
• • 4. Concurrent other malignant tumors.
• • 5. Patients with severe medical conditions deemed unsuitable for participation in this clinical study by the investigator, such as severe cardiopulmonary insufficiency or severe hepatic and renal dysfunction.
• • 6. Poor compliance.